About us
Our mission and vision
Freya’s mission is to provide women with better therapies for women with sexual dysfunction. There is a lack of effective treatment on the market today and those that exist have frequently reported side effects, require that they are taken daily even when not needed, or have administration methods which may be uncomfortable, such as injection.
We want women to feel comfortable taking charge of their sexual health by offering safe, convenient and effective options.
Board members
Nicole Hijnen | CEO
Nicole Hijnen has held several senior management and scientific positions worldwide. Following her PhD in biomedical engineering, she worked at Philips in a variety of roles from scientist to commercial director. Her commercialization experience in the medical device industry covers both EU and US markets. Nicole is also a non-executive board member for a medtech company, and acts as an angel investor.
Marcel Wijma | CBO & Founder
Marcel is an economist who has worked in equity analysis for nearly 25 years, specializing in healthcare. He is the founder of Van Leeuwenhoeck Research, which conducts independent financial research and due diligence for investors in life science companies. Marcel is one of the Executive Directors of Freya Pharma Solutions.
Christa van Kan | Director Clinical Operations
Christa was most recently Interim Director Clinical Operations at Healx, a Cambridge (UK) based AI drug discovery company. Prior to Healx, she had a long-term tenure as Project Director, Director Clinical Operations, Clinical Research Associate, and Research Assistant at PSR Group, a Dutch contract research organization (CRO). Christa holds an MSc degree in Biomedical Sciences from the State University Leiden in The Netherlands.
Dr. Jan van der Mooren | MD, PhD, MSc
Chief Medical Officer
Chairman of the Scientific Advisory Board
Jan is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology. He has been involved in clinical research in women’s health since 1990 and until recently has been Senior Director at the Danone Nutricia Research Centre in Utrecht. Jan will head the steering committee which is overseeing the Phase 3 clinical trial of Lybrido, and has joined Freya Pharma Solutions as CMO in April 2022.
Manuel Voll | Executive Advisor
Manuel is an executive advisor who combines almost three decades of (inter)national experience to find innovative solutions for the complex challenges healthcare stakeholders are facing, and support organizational leadership becoming more effective. He has worked for several healthcare and life science corporations, including Bristol-Myers Squibb, IQVIA and Organon, through which he gained extensive international experience in women’s health. Manuel is highly regarded as a visionary strategist and thought leader in managing commercial challenges.
Scientific Advisory Board
Dr. Giovanni Corona | MD, PhD
Endocrinologist and Andrologist, Maggiore-Bologna Hospital, Bologna, Italy
President-Elect of the European Society for Sexual Medicine
Prof. Annamaria Giraldi | MD, PhD
Professor of Clinical Sexology, University of Copenhagen, DK
Former President of the International Society for Sexual Medicine (ISSM)
Dr. Irwin Goldstein | MD, IF
Director of Sexual Medicine at Alvarado Hospital, San Diego, USA
Editor-in-Chief of Sexual Medicine Reviews
Sue Goldstein | BA, CCRC, AASECT-CSE, IF
Sexuality Educator and Clinical Research Manager at San Diego Sexual Medicine, San Diego, USA
President of the International Society for the Study of Women’s Sexual Health (ISSWSH)
Prof. Sheryl Kingsberg | PhD
Chief of the Division of Behavioral Medicine, University Hospitals Cleveland Medical Center, Cleveland, USA
Former President of The North American Menopause Society and The International Society for the Study of Women’s Sexual Health (ISSWSH)
Prof. Rossella Nappi | MD, PhD
Professor of Obstetrics and Gynaecology and Director of the Reproductive Medicine, Gynaecological Endocrinology & Menopause Unit, University of Pavia, Italy
Prof. Cobi Reisman | MD, PhD
Medical director of Flare Health institute, Amstelveen, NL
Co-Director of the European Society for Sexual Medicine, School of Sexual Medicine
Dr. Rachel Rubin | MD, IF
Urologist and Sexual Medicine Specialist, Medstar Georgetown University, Washington D.C., USA
Education Chair for the International Society for the Study of Women’s Sexual Health (ISSWSH)
Prof. Linda Vignozzi | MD, PhD
Associate Professor of Endocrinology, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy
Contract Research Organisation (CRO)
CR2O BV is leading the preparation, execution and reporting of Freya’s Lybrido Phase 3 clinical trial. CR2O is a full-service clinical contract research organization aimed at developing innovative treatments for unmet medical needs. www.cr2o.nl
Discover the latest news about HSDD/Freya
Scientific Advisory Board
Dr. Jan van der Mooren | MD, PhD, MSc
Chief Medical Officer
Chairman of the Scientific Advisory Board
Jan is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology. He has been involved in clinical research in women’s health since 1990 and until recently has been Senior Director at the Danone Nutricia Research Centre in Utrecht. Jan will head the steering committee which is overseeing the Phase 3 clinical trial of Lybrido, and has joined Freya Pharma Solutions as CMO in April 2022.
Dr. Giovanni Corona | MD, PhD
Endocrinologist and Andrologist, Maggiore-Bologna Hospital, Bologna, Italy
President-Elect of the European Society for Sexual Medicine
Prof. Annamaria Giraldi | MD, PhD
Professor of Clinical Sexology, University of Copenhagen, DK
Former President of the International Society for Sexual Medicine (ISSM)
Dr. Irwin Goldstein | MD, IF
Director of Sexual Medicine at Alvarado Hospital, San Diego, USA
Editor-in-Chief of Sexual Medicine Reviews
Sue Goldstein | BA, CCRC, AASECT-CSE, IF
Sexuality Educator and Clinical Research Manager at San Diego Sexual Medicine, San Diego, USA
President of the International Society for the Study of Women’s Sexual Health (ISSWSH)
Prof. Sheryl Kingsberg | PhD
Chief of the Division of Behavioral Medicine, University Hospitals Cleveland Medical Center, Cleveland, USA
Former President of The North American Menopause Society and The International Society for the Study of Women’s Sexual Health (ISSWSH)
Prof. Rossella Nappi | MD, PhD
Professor of Obstetrics and Gynaecology and Director of the Reproductive Medicine, Gynaecological Endocrinology & Menopause Unit, University of Pavia, Italy
Prof. Cobi Reisman | MD, PhD
Medical director of Flare Health institute, Amstelveen, NL
Co-Director of the European Society for Sexual Medicine, School of Sexual Medicine
Dr. Rachel Rubin | MD, IF
Urologist and Sexual Medicine Specialist, Medstar Georgetown University, Washington D.C., USA
Education Chair for the International Society for the Study of Women’s Sexual Health (ISSWSH)
Prof. Linda Vignozzi | MD, PhD
Associate Professor of Endocrinology, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy
Contract Research Organisation (CRO)
CR2O BV is leading the preparation, execution and reporting of Freya’s Lybrido Phase 3 clinical trial. CR2O is a full-service clinical contract research organization aimed at developing innovative treatments for unmet medical needs. www.cr2o.nl
Discover the latest news about HSDD/Freya
Freya Pharma Solutions B.V.
Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands